BCBS of Rhode Island partners with AI company to identify chronic conditions

Blue Cross & Blue Shield of Rhode Island partnered with Diagnostic Robotics to assist in identifying risks for chronic conditions in its members to curb unnecessary hospitalizations.

Advertisement

According to an April 6 press release, Diagnostic Robotics’ use of artificial intelligence will assist payers, providers and patients in the diagnosis and treatment of conditions including behavioral health and congestive heart failure. 

Customizable tools will allow BCBSRI to identify and monitor members with rising health risks, such as obesity, the press release read.

A mobile app will enable members to find appropriate care in their network.

 

More articles on payers:
Lawsuit accuses BCBS of Massachusetts of systematically allowing overpayments
Nurse sues Highmark, accuses insurer of failing to pay OT
5 things to know about the Medicaid coverage ‘cliff’

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Artificial Intelligence

  • Hospitals are increasingly paying for artificial intelligence by the token, turning a once-obscure technical term into a line item finance…

  • Hospital leaders often measure cybersecurity readiness by asking whether their own environment is protected. Are systems patched? Is multifactor authentication…

Advertisement

Comments are closed.